Skip to main content

Advertisement

SpringerLink
Log in

Prostatakarzinomprophylaxe durch Nahrungsergänzungsmittel

Mehr als trügerische Hoffnung?

Prostate cancer prophylaxis by dietary supplements

More than just an illusion?

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Tumorprophylaxe an der Prostata ist theoretisch einfach – schwierig ist jedoch, dass keine entsprechenden Testmethoden zur Verfügung stehen. Das Thema: „Prostatakarzinomprophylaxe durch Nahrungsergänzungsmittel“ bleibt schwierig. Noch gibt es keine wirklich sicheren Daten. Der psychologische Aspekt, selbst aktiv zum Erfolg einer Therapie beitragen zu wollen und zu können, ist durchaus ein nicht zu vernachlässigender Aspekt, solche Nahrungsergänzungsmittel zu akzeptieren. Und es gibt Studien, die zeigen, dass ein gewisser hilfreicher Effekt vorhanden zu sein scheint. Aus diesen Überlegungen heraus entsteht die Frage, ob man nicht sogar eine Karzinomprophylaxe daraus entwickeln könnte. Nachfolgend wird der Stand im Frühjahr 2014 vorgestellt.

Abstract

Prophylaxis of tumors of the prostate gland is theoretically simple but what makes it difficult is that no appropriate test methods are available. The topic of prostate cancer prophylaxis by dietary supplements remains difficult as there are still no really certain data. The psychological aspect of wanting and being able to actively contribute to success of a therapy oneself, is absolutely not an aspect to be ignored to accept such dietary supplements. There are also studies which show that a certain helpful effect seems to be present. From these considerations the question arises whether cancer prophylaxis could be developed from this. This article presents the state of the art in early 2014.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Kernaussagen werden in der Literatur angegeben, Details sind der Originalliteratur zu entnehmen.

Literatur

  1. Lippman SM, Klein EA, Goodman P et al (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(2):39–51

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Merkle W (2010) Prophylaxis and treatment of prostate cancers by nutrition supplements: a clinician’s view of facts and hope after the SELECT study. UIJ 9(1). doi:10.3834luij.1944-5784.2010.02.13

  3. Lu Y, Zhai L, Zeng J et al (2014) Coffee consumption and prostate cancer risk: an updated meta-analysis. Cancer Causes Control 25(5):591–604. doi:10.1007/s10552-014-0364-B

    Article  PubMed  Google Scholar 

  4. Itsiopoulos C, Hodge A, Kaimakis M (2009) Can the Mediterranean diet prevnt prostate cancer? Mol Nutr Food Res 53(2):227–239

    Article  CAS  PubMed  Google Scholar 

  5. Schmid H-P, Fischer C, Enegler DS et al (2011) Nutritional aspects of primary prostate cancer prevention. Recent Results Cancer Res 188:101–107

    Article  CAS  PubMed  Google Scholar 

  6. Grainger EM, Schwartz SJ, Wand S et al (2008) A combination of tomato and soy products form en with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer 60(2):145–141

    Article  CAS  PubMed  Google Scholar 

  7. Wilson KM, Bälter K, Möller E et al (2013) Coffee and risk of prostate cancer incidence and mortality in the cancer of the prostate in Sweden study. Cancer Causes Control 24(8):1575–1581

    Article  PubMed  Google Scholar 

  8. Geybels MS, Neuhouser ML, Wright JL et al (2013) Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control 24(11):1947–1954

    Article  PubMed  Google Scholar 

  9. Li Q, Kakizaki M, Sugawara Y et al (2013) Coffee consumption and the risk of prostate cancer: the Ohasi cohort study. Br J Cancer 108(11):2381–2389

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. MNT (2014) Pomgranate, green tea, turmeric and broccoli may help fight prostate cancer. MNT, London, http://www.medicalnewstoday.com/articles/261688.php

  11. Mayo-Klinik (2014) Prostate cancer prevention: ways to reduce your risk. Mayo-Klinik. http://www.mayoclinic.org

  12. Adjakly M, Ngollo M, Boiteux JP et al (2013) Genistein and daidzein: different molecular effects on prostate cancer. Anticancer Res 33(1):39–44

    CAS  PubMed  Google Scholar 

  13. Chiyomaur T, Yamamury S, Fukuhara S et al (2013) Genistein up-regulates tumor suppression microRNA-574-3p in prostate cancer. PLoS One 8(3):58929

    Article  Google Scholar 

  14. Hörmann V, Kuni-Diaka J, Durity M et al (2012) Anticancer activities of genistein-topotecan combination in prostate cancer cells. J Cell Mol Med 16(11):2631–2636

    Article  PubMed  Google Scholar 

  15. Zhang W, Wang Y, Chen T et al (2013) Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistent prostate cancer cells. Prostate 73(15):1681–1689

    Article  CAS  PubMed  Google Scholar 

  16. NCI (2013) Pomegranate: prostate cancer, nutrition and dietary supplements (PDQ). NCI, Bethesda. http://www.cancer.gov

  17. Senner-Liewen F, Liewen H, Cathomas R et al (2013) Dialy pomegranate intake has no impact on PSA leves in patients with advanced prostate cancer – results of a phase IIb randomized controlled trial. J Cancer 4(7):597–605

    Article  Google Scholar 

  18. NCI (2013) Green Tea. Prostate cancer, nutrition and dietary supplements (PDQ). NCI, Bethesda. http://www.cancer.gov

  19. Teichert F, Verschoyle RD, Greaves P et al (2010) Plasma metabolic profiling reveals age-dependeny of systemic effects of green tea polyphenols in mice with and without prostate cancer. Mol Biosyst 6(10):1911–1916

    Article  CAS  PubMed  Google Scholar 

  20. Bettuzzi S, Brausi M, Rizzi F et al (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grde prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of principle study. Cancer Res 66(2):1234–1240

    Article  CAS  PubMed  Google Scholar 

  21. Jatoi A, elision N, Burch PA et al (2003) a phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97(6):1442–1446

    Article  CAS  PubMed  Google Scholar 

  22. Boehm K, Borrellei F, Ernst E et al (2009) Green tea (Camellia sinensis) fopr the prevention of cancer. Cochrane Database Syst Rev 3:CD005004

    PubMed  Google Scholar 

  23. Montaguy JA, Butler LM, Wy AH et al (2012) Green an black tea intake in relation to prostate cancer risk among Singapore Chinese. Cancer Causes Control 23(10):1635–1641

    Article  Google Scholar 

  24. Kavitha C, Deep G, Gangar S et al (2014) Silibinin inhibits prostate cacner cells- and RANKL-induced osteoclastogenessis by targetin NFATc1, NF-kappaB and AP-1 activation in RAW264.7 cells. Mol Carcinog 53(3):169–180

    Article  CAS  PubMed  Google Scholar 

  25. Ting H, Deep G, Agarwal R (2013) Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 15(3):707–716

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Wu K, Zeng J, Zhu GD et al (2009) Silibinin inhibits prostate cacner invation, motility and migration by suppression viemntin and MMP-2 epxpression. Acta Pharmacol Sin 30(8):1162–1168

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Li G, Rivas P, Bedolla R et al (2013) Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/s6K axis. Cancer Prev Res (Phila) 6(1):27–39

    Article  Google Scholar 

  28. Ganapathy S, Chen Q, Singh K et al (2010) Resveratrol enhances antitumor ectivity of TRAIL in prostate cancer xenografty through activation of FOXO transcription factor. PLoS One 5(12):15627

    Article  Google Scholar 

  29. Jeaong NY, Yoon G, Rho JH et al (2011) The novel resveratrol analo HS-1793-induced polyploidy LNCaP prostate cancer cells are vulnerabl to downregulation ob Bcl-xL. Int J Oncol 38(6):1597–1604

    Google Scholar 

  30. Klink JC, Tewar AK, Masko EM et al (2013) Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through prardoxical effets on oncogenic pathwasy. Prostate 73(7):754–762

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Chan HT, Chou CT, Chen IL et al (2013) Mechanisms of resveratrol-induced changes in [Ca(2+)]I and cell viability in PC3 human prostate cancer cells. J Recept Signal Transduct Res 333(5):298–303

    Article  Google Scholar 

  32. Sheth S, Jajoo S, Kaur T et al (2012) Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 7(12):51655

    Article  Google Scholar 

  33. Iguchi K, Toyama T, Ito T et al (2012) Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells. J Androl 33(6):1208–1215

    Article  CAS  PubMed  Google Scholar 

  34. Kai L, Levenson AS (2011) Combination of resveratrol and antiandrogen flutamide ha synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res 31(10):3323–3330

    CAS  PubMed  Google Scholar 

  35. Kim DH, Hossain MA, Kim MY et al (2013) A novel resveratrol analoge, HS-1793, inhibis hypocia-induces HIF-1alpha and VEGF expression, and migration in human prostate cancer cells. Int J Oncol 43(6):1915–1924

    CAS  PubMed  Google Scholar 

  36. Dhar S, Hicks C, Levension AS (2011) Resveratrol and prostate cancer: primision role for microRNAs. Mol Nutr Food Res 55(8):1219–1229

    Article  CAS  PubMed  Google Scholar 

  37. Chen Q, Ganapathy S, Sing KP et al (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5(12):15288

    Article  Google Scholar 

  38. Narayanan NK, Nargi D, Randolph C et al (2009) Liposoe encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1–8

    Article  CAS  PubMed  Google Scholar 

  39. Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutiv roles or curcumin: lesions learned from clinical trials. AAPS J 15(1):195–218

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Cretju E, Trifan A, Vasincu AI et al (2010) Plant-derived anticancer agents – curcumin in cancer prevention and treatment. Rev Med Chir Soc Med Nat Iasi 13(4):343–349

    Google Scholar 

  41. Wei Y, Zhou D, Wand H et al (2012) Effects of pyridine analogs of curcumin on growth, apoptosis and NF-kappaB activity in prostate cancer PC-3 cells. Anticancer Res 116(4):1223–1229

    Google Scholar 

  42. Teiten MH, Gaascht F, Cronaur M et al (2011) Antiproliferative ptential of curcumin in androgen-dependent prostate cancer cells occurs through modulation of the Wingless signaling pathway. Int J Oncol 38(3):603–611

    CAS  PubMed  Google Scholar 

  43. Sundram V, Chauhen SC, Ebeling M et al (2012) Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinease D1. PLoS One 7(4):35368

    Article  Google Scholar 

  44. Fajardo AM, MacKenzie DA, Ji M et al (2012) The curcumin analog ca27 dow-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. Prostate 72(6):612–625

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Guo H, Xu YM, Ye ZQ et al (2013) Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulation the expression of IkappaBalpha, c-Jun and androgen receptor. Pharmazie 68(6):431–434

    CAS  PubMed  Google Scholar 

  46. Cheng TA, Chen WC, Lin YY et al (2013) Curcumin-targeting pericellular serine protease matriptase rol in suppression of prostate cancer cell invation tumor growth and metastasis. Cancer Prev Res (Phila) 6(5):495–505. doi:10.1007/s/104953013-0947-y

    Article  Google Scholar 

  47. Ide H, Tokiwa S, Sakamaki K et al (2010) Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70(10):1127–1133

    Article  CAS  PubMed  Google Scholar 

  48. Gardner CD, Oelrich B, Liu JP et al (2009) Prostatic sy isoflavone concentrations exceed serum levels after dieatary supplementation. Prostate 69(7):719–726

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Yatkin E, Polari L, Laajala TD et al (2014) Novel lignan an stilbenoid misture shows anticarcinogenic efficacy in preclinical PC-3M-luc2 prostate cancer model. PLoS One 9(4):93764

    Article  Google Scholar 

  50. Peuhu E, Rivero-Müller A, Stykki H et al (2010) Inhibition of AKT signaling by the lignan matairenisl sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 29(6):898–908

    Article  CAS  PubMed  Google Scholar 

  51. Zhou YJ, Liu YE, Cao JG et al (2009) Viexins, nature-derived lignin compounds induce apoptosis and suppress tumor growth. Clin Cancer Res 15(16):5161–5189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Azrad M, Vollmer RT, Madden J et al (2013) Flaxseed-derived enterolactone is inversely asiciatde with tumor cell proliferation in men with localize prostate cancer. J Med Food 16(4):357–360

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Goodman M, Bostick RM, Ward KC et al (2006) Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer 55:13–20

    Article  CAS  PubMed  Google Scholar 

  54. Zhang X, Wang Q, Neil B et al (2010) Effect of lycopene on androgen receptor and prostate-specifig antigen velocity. Chin Med J (Engl) 123(16):2231–2236

    Google Scholar 

  55. KIM HS, Bowen P, Chen L et al (2003) Effects of tomato sauce comsumption on apoptotic cell death in prostate benign hyperplasia and cancer. Nutr Cancer 47(1):40–47

    Article  CAS  PubMed  Google Scholar 

  56. Tang Y, Parmaktiar B, Simoneau AR et al (2011) Lykopene enhances docetaxel’s effect in castration-resistent prostate cancer associated with insulin-like growth factor I receptor levels. Neoplasia 13(2):108–119

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Ilic D, Forbes KW, Hassed C (2011) Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev 11:CD008007

    PubMed  Google Scholar 

  58. Zu K, Mucci L, Rosner BA et al (2014) Dietary lycopene, angiogenesis and prostate cancer: a prospective study in the prostate-specifi antigen era. J Natl Cancer Inst 106(2):430

    Article  Google Scholar 

  59. Soares NCP, Teodoro AJ, Oliveira FL et al (2013) Influence of lycopene on cell viability cell cycle and apoptosis of human prostate cancer and benign hyperplastic cells. Nutr Cancer 65(7):1076–1085

    Article  CAS  Google Scholar 

  60. Ford NA, Elsen AC, Zuniga K et al (2011) Lycopene and apo-12’-lycopenal reduce cell proliferation and alter cell cycle progression in human prostate cancer cells. Nutr Cancer 64(2):256–263

    Article  Google Scholar 

  61. Holzapfel NP, Holzapfel BM, Champ S et al (2013) The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanism to clinical evidence. Int J Mol Sci 14(7):14620–14646

    Article  PubMed Central  PubMed  Google Scholar 

  62. Konijeti R, Henning S, Moro A et al (2010) Chemoprecvention of prostate cancer with lycopene in the TRAMP model. Prostate 70(14):1547–1554

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Ilic D (2014) Lycopene for the prevention and treatment of prostate disease. Recent Results Cancer Res 202:109–114

    Article  PubMed  Google Scholar 

  64. Haseen F, Cantwell MM, O’Sullivan JM et al (2009) Is there a benefit from lycopene supplementation in man with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 12(4):325–332

    Article  CAS  PubMed  Google Scholar 

  65. Talvas J, Caris-Veyrat C, Guy L et al (2010) Differential effects of lycopene consumed in tomato paste and lycopene in the form of a purified extract on target genes of cancer prostatic cells. Am J Clin Nutr 123(16):2231–2236

    Google Scholar 

  66. Vaishampayan U, Hussain M, Banerjee M et al (2007) Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 59(1):1–7

    Article  CAS  PubMed  Google Scholar 

  67. Trejo-Solis C, Pedraza-Chaverri J, Torres-Ramos M et al (2013) Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition. Evid Based Complement Alternat Med 2013:705121

    Article  PubMed Central  PubMed  Google Scholar 

  68. Altavilla D, Bitto A, Plito F et al (2011) The combination of serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth. J Urol 186(4):1524–1529

    Article  CAS  PubMed  Google Scholar 

  69. Paluuy P, Colangelo M, Simone R et al (2010) Lycopene induces cell growth inhibition by altering mevalonate pathway and ras signaling in cancer cell lines. Carcinogenesis 31(10):1813–1821

    Article  Google Scholar 

  70. NIH (2013) Fish oil. NIH, Bethesda. http://www.nlm.nih.gov

  71. Medscape (2013) Prostate cancer and Nutrition. Drug & Reference information. Medscape, New York. http://www.medscape.com

  72. Huffingtonpost (2013) Recent study implicates omega-3 fatty acids in prostate cancer: is there reliable information? Huffingtonpost, Huffington. http://www.huffingtonpost.com. Zugegriffen: 07. Juli 2013

  73. Szymanski KM, Wheeler DC, Mucci LA et al (2010) Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 92:1223–1233

    Article  CAS  PubMed  Google Scholar 

  74. Lifeextension (2013) Fish and prostate cancer risk: fact of fiction. Lifeextension, Fort Lauderdale. http://www.lef.org

  75. Simon S (2014) Omega-3 fatty acids links to increase in prostate cancer risk. ACS, Atlanta. http://www.cancer.org

  76. Atawodi SE (2011) Nigerian foodstuffs with prostate cancer chemopreventive polyphenoles. Infect Agent Cancer 6(Suppl 2):99

    Google Scholar 

  77. Abdulah R, Kobayashi K, Yamazaki C et al (2011) Molecular targets of selenium in prostate cancer prevention (review). Int J Oncol 39(2):301–309

    CAS  PubMed  Google Scholar 

  78. Christensen MJ, Qunier TE, Nakken HL et al (2013) Combination effects of dietary soy and methlsenenocysteine in a mouse model of prostate cancer. Prostate 73(9):986–995

    Article  CAS  PubMed  Google Scholar 

  79. Dennert G, Zwahlen M, Brinkmann M et al (2011) Selenium for preventing cancer. Cochrane Database Syst Rev 5:CD005195

    PubMed  Google Scholar 

  80. Lunoe K, Gabel-Jensen C, Stürüp S et al (2011) Investigation oft he selenium metabolism in cancer cell lines. Metallomics 3(2):162–168

    Article  CAS  PubMed  Google Scholar 

  81. Takata Y, Morris JS, King IB et al (2009) Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue. Prostate 69(15):1635–1642

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  82. Gundimes U, Schiffman JE, Chhabra D et al (2008) Locally generated methylselenic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells. J Biol Chem 283(50):34519–34531

    Article  Google Scholar 

  83. Steinbecher A, Mapln C, Hesketh J et al (2010) Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study on European men. Cancer Epidemiol Biomarkers Prev 19(11):2958–2968

    Article  Google Scholar 

  84. Geybels MS, Hutter CM, Kwon EM et al (2013) Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 73(7):734–742

    Article  CAS  PubMed  Google Scholar 

  85. Penney KL, Li H, Micci LA et al (2013) Selenoprotein P genetic variants and mrna expression; circulating selenium, and prostate cancer risk and survival. Prostate 73(7):700–705

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  86. Chan JM, Oh WK, Xie W et al (2009) Plasma selenium, manganese superoxide dismutase and intermediate- or high-risk prostate cancer. J Clin Oncol 27(22):3577–3583

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  87. Hurst R, Hooper L, Norat T et al (2012) Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 96(1):111–122

    Article  CAS  PubMed  Google Scholar 

  88. Stratton MA, Algotar AM, Ranger-Moore J et al (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila) 3(8):1035–1043

    Article  Google Scholar 

  89. Rayman MP, Combs GF Jr, Waters DJ (2009) Selenium and vitamin E supplementation for cancer prevention. JAMA 301(18):1876–1877

    Article  CAS  PubMed  Google Scholar 

  90. Geybels MA, Verhage Bas AJ, Schooten FJ van et al (2013) Advanced prostate cancer risk in relation to toenail selenium levels. J Natl Cancer Inst 105(18):13941401

    Article  Google Scholar 

  91. Bauer CM, Ishak MB, Johnson EK et al (2012) Prevalence and correlates of vitamin and supplement usage among men with a family history of prostate cancer. Integr Cancer Ther 11(2):83–89

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  92. Philippou Y, Hadjipavlou M, Khan S et al (2013) Complementary and alteranative medicine (CAM) in prostate and bladder cancer. BJU Int 112(8):1073–1079

    Article  CAS  PubMed  Google Scholar 

  93. Paschos A, Pandya R, Cuivenvoorden WCM et al (2013) Oxidatvie stress in prostate cancer: changing research concepts towards a noval prardigm for prevention and therapeutics. Prostate Cancer Prostatic Dis 16(3):217–225

    Article  CAS  PubMed  Google Scholar 

  94. Huncharek M, Muscat J, Kupelnick B (2009) Colorectal cancer risk and dietary intake of calcium, Vitamin D and diary products: a meta-analysis of 26335 cases from 60 observational studies. Nutr Cancer 61(1):47–69

    Article  CAS  PubMed  Google Scholar 

  95. Van Veldhiuzen PJ, Taylor SA, Williamson S et al (2000) Treatmen of vitamin D deficiency in patients with metastaic prostate cancer may improve bone pain and muscle strength. J Urol 163:187–190

    Article  Google Scholar 

  96. Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Women’s health initative investigators. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696

    Article  CAS  PubMed  Google Scholar 

  97. AACR (2012) Oral vitamin D supplements reduced levels of Ki67 in prostate cancer cells. AACR, Philadelphia. http://www.sciencedaily.com. Zugegriffen: 31.03.2012

  98. Hsu JW, Yasmin-Karim S, King MR et al (2011) Suppression of prostate cancer cll rolling an dadhesion to entothelium by 1,25-dihydroxyviatmin D3. Am J Pathol 178(2):872–880

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Zheng Y, Zhou H, Ooi LL et al (2011) Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 71(9):1012–1021

    Article  CAS  PubMed  Google Scholar 

  100. Gavrilov V, Leibovich Y, Ariad S et al (2010) A combined pretreatment of 1,15-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionized radiation on prostatic cancer cells. J Steroid Biochem Mol Biol 121(1–2):391–394

  101. Holt SK, Kwon EM, Koopmeiners JS et al (2010) Viatmin D pathway gene variants and prostate cancer prognosis. Prostate 70(13):1448–1460

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  102. Newson-Davis TE, Kenny LM, Ngan S et al (2009) The promiscuous receptor. BJU Int 104(9):1204–1207

    Article  Google Scholar 

  103. Klein EA, Thompson IM, Tangen CM et al (2011) Vitamin E and the risk of prostate cancer (SELECT). JAMA 306(14):1549–1556. https://jama.jamanetwork.com

  104. Okamoto R, Delansome R, Wakimoto N et al (2012) Inecacitol, an analog of 1α,25 (OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 130(10):2464–2473. doi:10.1002/ijc.26279

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. W. Merkle gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Fachbereich Urologie II, DKD Helios Klinik Wiesbaden, Stiftung Deutsche Klinik für Diagnostik GmbH, Aukammallee 33, 65191, Wiesbaden, Deutschland

    W. Merkle

Authors
  1. W. Merkle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Merkle.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Merkle, W. Prostatakarzinomprophylaxe durch Nahrungsergänzungsmittel. Urologe 53, 1610–1619 (2014). https://doi.org/10.1007/s00120-014-3614-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-014-3614-1

Schlüsselwörter

Keywords

Search

Navigation